MIT chemical engineers have developed a new sensor that lets them see inside cancer cells and determine whether the cells are responding to a particular type of chemotherapy drug.
The sensors, which detect hydrogen peroxide inside human cells, could help researchers identify new cancer drugs that boost levels of hydrogen peroxide, which induces programmed cell death. The sensors could also be adapted to screen individual patients’ tumors to predict whether such drugs would be effective against them.
“The same therapy isn’t going to work against all tumors,” says Hadley Sikes, an associate professor of chemical engineering at MIT. “Currently there’s a real dearth of quantitative, chemically specific tools to be able to measure the changes that occur in tumor cells versus normal cells in response to drug treatment.”
Sikes is the senior author of the study, which appears in the Aug. 7 issue of Nature Communications. The paper’s first author is graduate student Troy Langford; other authors are former graduate students Beijing Huang and Joseph Lim and graduate student Sun Jin Moon.
Tracking hydrogen peroxide
Cancer cells often have mutations that cause their metabolism to go awry and produce abnormally high fluxes of hydrogen peroxide. When too much of the molecule is produced, it can damage cells, so cancer cells become highly dependent on antioxidant systems that remove hydrogen peroxide from cells.
Drugs that target this vulnerability, which are known as “redox drugs,” can work by either disabling the antioxidant systems or further boosting production of hydrogen peroxide. Many such drugs have entered clinical trials, with mixed results.
“One of the problems is that the clinical trials usually find that they work for some patients and they don’t work for other patients,” Sikes says. “We really need tools to be able to do more well-designed trials where we figure out which patients are going to respond to this approach and which aren’t, so more of these drugs can be approved.”
To help move toward that goal, Sikes set out to design a sensor that could sensitively detect hydrogen peroxide inside human cells, allowing scientists to measure a cell’s response to such drugs.
Existing hydrogen peroxide sensors are based on proteins called transcription factors, taken from microbes and engineered to fluoresce when they react with hydrogen peroxide. Sikes and her colleagues tried to use these in human cells but found that they were not sensitive in the range of hydrogen peroxide they were trying to detect, which led them to seek human proteins that could perform the task.
Through studies of the network of human proteins that become oxidized with increasing hydrogen peroxide, the researchers identified an enzyme called peroxiredoxin that dominates most human cells’ reactions with the molecule. One of this enzyme’s many functions is sensing changes in hydrogen peroxide levels.
Langford then modified the protein by adding two fluorescent molecules to it — a green fluorescent protein at one end and a red fluorescent protein at the other end. When the sensor reacts with hydrogen peroxide, its shape changes, bringing the two fluorescent proteins closer together. The researchers can detect whether this shift has occurred by shining green light onto the cells: If no hydrogen peroxide has been detected, the glow remains green; if hydrogen peroxide is present, the sensor glows red instead.
The researchers tested their new sensor in two types of human cancer cells: one set that they knew was susceptible to a redox drug called piperlongumine, and another that they knew was not susceptible. The sensor revealed that hydrogen peroxide levels were unchanged in the resistant cells but went up in the susceptible cells, as the researchers expected.
Sikes envisions two major uses for this sensor. One is to screen libraries of existing drugs, or compounds that could potentially be used as drugs, to determine if they have the desired effect of increasing hydrogen peroxide concentration in cancer cells. Another potential use is to screen patients before they receive such drugs, to see if the drugs will be successful against each patient’s tumor. Sikes is now pursuing both of these approaches.
“You have to know which cancer drugs work in this way, and then which tumors are going to respond,” she says. “Those are two separate but related problems that both need to be solved for this approach to have practical impact in the clinic.”
The Latest on: Cancer therapy
[google_news title=”” keyword=”cancer therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer therapy
- At 52, Shannen Doherty Reveals Stage 4 Cancer Has Spread to Bones: ‘I’m Not Done’on December 1, 2023 at 4:57 am
This is what cancer can look like.” On the flip side ... She’s optimistic about having a place in new clinical trials that could advance her treatment. Until then, she’s simply glad to be here. “I ...
- Researchers translate a hypothesis into a personalized treatment for canceron December 1, 2023 at 4:15 am
"Our T-cells, one of our immune cells, are great at killing cancer cells—if they can see them," says Zemp. "This therapy works by genetically engineering a patient's T-cells to detect cancer-specific ...
- FDA warns breakthrough cancer treatment might cause canceron December 1, 2023 at 4:11 am
In 2017, the U.S. Food and Drug Administration (FDA) approved a breakthrough treatment for blood cancer. But now, the agency cautions the treatment is not without risks and appears to have caused ...
- Cancer patients with opioid use disorder face obstacles to treatmenton December 1, 2023 at 4:03 am
A cancer diagnosis can greatly disrupt treatment with methadone, a medication used to treat patients with opioid use disorder, according to a perspective piece published in the New England Journal of ...
- SAH Updating Radiation Treatment Units – Requires Interruption of Services for Five Monthson December 1, 2023 at 3:48 am
Cancer Care Ontario mandates that radiation treatment units be replaced every 12 years and our unit is now due for replacement. This will result in the interruption of radiation treatment services for ...
- Prostate cancer focal therapy could improve costs and patient outcomeson December 1, 2023 at 3:23 am
“Focal therapy represents good value for money in the NHS… [with] lower side effects and improved quality of life compared to traditional treatments [and] could benefit about 10,000 patients who are ...
- Gene Therapy Shrinks Liver Cancer in Miceon December 1, 2023 at 1:53 am
According to research, inhibiting the galectin 1 protein, which is often over-expressed in hepatocellular carcinoma (HCC) using gene therapy can shrink HCC and increase the number of killer T cells ...
- Kelowna cancer trial saves 'palliative' patienton December 1, 2023 at 1:09 am
Allan Wolfram’s Stage 4 esophageal cancer diagnosis in 2019 was a shock, but the journey that came after is almost as surprising. The diagnosis would bring Wolfram, then 63 and living in Winnipeg, ...
- SOUND OFF: NDP cancer care crisis deepenson November 30, 2023 at 10:31 am
CANCER IS A DISEASE that cannot wait. I spoke these words in the Legislature on November 9, when I told the heart-wrenching story of a constituent who was told she would have to wait 17 weeks for ...
via Bing News